Farideh Z. Bischoff

Farideh Z. Bischoff is the CEO and Chief Scientific Officer at FreMon Scientific. Before that, they were the Vice President of Clinical Research at Imagion Biosystems, Inc., where they specialized in nanoparticles guided molecular profiling. Prior to that, they were the Chief Development Officer at Menarini Silicon Biosystems.

Bischoff has also been with Biocept, Inc. where they served as the Vice President of Translational Research and Clinical Development. Farideh is credited with leading the team that successfully validated Biocept's first commercial oncology product, OncoCEE-BR. Bischoff has also served as the primary liaison and facilitator of several basic science and clinical research collaborations with investigators at MD Anderson Cancer Center.

Farideh Z. Bischoff has a Ph.D. in Cancer Biology from the University of Texas Health Science Center at Houston (UTHealth Houston), and a B.S. in Biochemistry from Stony Brook University.

Some direct reports include William Davey - VP, Product Management & Design, Frederick J. Thacher - Co-Founder & Chief Development Officer, and Lindia Fabian - National Accounts Director.